MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Rating of “Hold” by Brokerages

MiNK Therapeutics, Inc. (NASDAQ:INKT) has received a consensus recommendation of “Hold” from the five ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $35.00.

Separately, Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 19th.

MiNK Therapeutics Price Performance

Shares of NASDAQ:INKT opened at $9.57 on Wednesday. The stock has a market cap of $44.88 million, a price-to-earnings ratio of -3.16 and a beta of 0.35. MiNK Therapeutics has a 12 month low of $6.34 and a 12 month high of $76.00. The stock’s 50 day moving average price is $11.43 and its 200 day moving average price is $12.59.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC lifted its stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,247 shares of the company’s stock after acquiring an additional 1,441 shares during the quarter. Geode Capital Management LLC owned 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent reporting period. 2.87% of the stock is owned by institutional investors and hedge funds.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.